News & Updates

NanoView Biosciences Launches EPIC Study to Investigate Impact of Exosome-Associated Biomarkers for Immuno-Oncology


Excerpt from the Press Release: BOSTON, April 15, 2021 /PRNewswire/ — NanoView Biosciences Inc. (“NanoView”), a leading biomarker characterization company in the emerging field of extracellular vesicle biology, today announced a collaboration agreement with Beth Israel Deaconess Medical Center (“BIDMC”) to study the involvement of biomarkers carried by exosomes in patients undergoing immune checkpoint inhibitor therapy (“ICIT”) for…

Read More

Windtree Therapeutics Announces New Istaroxime Expedited Review Filing of Patent


Excerpt from the Press Release: WARRINGTON, Pa., April 19, 2021 /PRNewswire/ — Windtree Therapeutics, Inc. (NasdaqCM: WINT) (“Windtree” or the “Company”), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced it has filed a Track One prioritized application with the United States Patent and Trademark Office (USPTO)…

Read More

Translate Bio Announces Publication of Preclinical Results of COVID-19 mRNA Vaccine Candidate MRT5500 in npj Vaccines


Excerpt from the Press Release: LEXINGTON, Mass., April 19, 2021 (GLOBE NEWSWIRE) — Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced the peer-reviewed publication of preclinical results of its COVID-19 vaccine candidate, MRT5500, in the journal npj Vaccines. Preclinical evaluation of MRT5500 demonstrated a favorable immune response profile against SARS-CoV-2 and…

Read More

Arch Therapeutics Provides Corporate Update on Commercialization Efforts and Clinical Results


Excerpt from the Press Release: FRAMINGHAM, Mass., April 19, 2021 (GLOBE NEWSWIRE) — Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today provided the following corporate update, in line with its commitment to maintain continuing dialogue with investors and other stakeholders on the progress and…

Read More

Scientists Reverse Engineer mRNA Sequence of Moderna Vaccine


Excerpt from the Article: Leftover drops in vials of Moderna’s COVID-19 vaccine allowed a group of researchers from Stanford University to determine the sequence of the mRNA for SARS-CoV-2’s spike protein that is used in the immunization, Motherboard reported March 29. The sequence has been posted on the open-access website GitHub. “Sharing of sequence information…

Read More

Moderna Highlights Publication of Antibody Persistence Data of its COVID-19 Vaccine out to 6 Months in the New England Journal of Medicine


Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today highlighted the publication of antibody persistence data out to 6 months following the second dose of the Moderna COVID-19 Vaccine in The New England Journal of Medicine. “We are pleased that this new…

Read More

Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients


Excerpt from the Press Release: INDIANAPOLIS, April 8, 2021 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today results of COV-BARRIER, a Phase 3 study evaluating baricitinib 4 mg once daily plus standard of care (SoC) versus placebo plus SoC. The trial did not meet statistical significance on the primary endpoint, which…

Read More

Strongbridge Biopharma plc Announces Publication of Diabetes Subgroup Analysis from Phase 3 SONICS Study of RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome in Frontiers in Endocrinology


Excerpt from the Press Release: DUBLIN, Ireland and TREVOSE, Pa., April 07, 2021 (GLOBE NEWSWIRE) — Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that results from a subanalysis of patients with diabetes mellitus from the…

Read More

Register for our upcoming “How Using Statisticians Early Plays A Crucial Role In Optimizing Clinical Trials” virtual networking meeting!


Our April virtual networking meeting is next week! Join Heather and Christopher, and their guest, John Amrhein from McDougall Scientific on April 21st, 8 pm EST for this exciting discussion on the crucial need to involve statisticians early in the clinical trial design process! To register for your complimentary ticket, click the image or button…

Read More

Invitae joins NIH-sponsored study aimed at improving understanding of the links between genes and cancer, heart disease and other conditions


Excerpt from the Press Release: SAN FRANCISCO, April 8, 2021 /PRNewswire/ — Invitae Corporation (NYSE: NVTA), a leading medical genetics company, has joined eMERGE Network, a nationwide effort organized and funded by the National Human Genome Research Institute (NHGRI) that connects genetic data and electronic medical record (EMR) systems to advance the use of genetics…

Read More

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?